Paclitaxel can promote the polarisation to DCs and the proliferation and activity of CD8+ T cells and NK cells to exert stronger anti-tumour effects, which leads to a higher sensitivity to paclitaxel in the NMlow/TMEhigh group61. Here, CD8A is linked to neoplasm.